Trial Information
The Study of New RIC Regimen of BuFlu in Older or Intolerable Patients With Hematologic Malignant Diseases
Inclusion Criteria:
- diagnosed of hematologic malignant disease
- will undergo HLA matced HSCT
- age >=55years
- <55year and intolerable to standard myeloablative conditioning
Exclusion Criteria:
- KPS status <70
- cardiac EF<50%
- creatine clearance <50 ml/min
- ALT more than 10 times of upper normal limit
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Prospective
Outcome Measure:
stem cell engraftment
Outcome Time Frame:
30day post transplantation
Safety Issue:
No
Principal Investigator
XiaoJun Huang, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Peking University People's Hospital, Department of Hematology
Authority:
China: Ministry of Health
Study ID:
PKUIH-201303
NCT ID:
NCT01828619
Start Date:
February 2013
Completion Date:
Related Keywords:
- Leukemia
- Myelodysplastic Syndrome
- Hematopoietic Stem Cell Transplantation
- Busulfan
- Fludarabine
- Leukemia
- Myelodysplastic Syndromes
- Preleukemia